Many popular tourist attractions and trekking routes in Bhutan and Nepal are situated between 3000 and 6000m in elevation. High-altitude emergencies are becoming more common and medical providers must be aware of the practical and medical issues in managing these disorders. We reflect on the challenges in providing high-altitude emergency medical services in Bhutan and Nepal.
Rheumatic Heart Disease (RHD) remains a significant public health problem with high morbidity and mortality in children and young adults from lower-middle income countries like Nepal. However, a nation-wide database of the disease is lacking for designing effective future prevention and control programmes and strategies. The aim of our study is to estimate the prevalence of RHD in school-attending Nepalese children. We performed a cross-sectional descriptive analysis of a nationally representative database of Nepal Heart Foundation (NHF) national RHD screening programme which included school-attending Nepalese children between five and sixteen years of age. The screening was conducted between May 2015 and March 2020 in 236 schools, representing all seven provinces, across all three ecological zones of Nepal. Transthoracic two-dimensional echocardiography was performed in all eligible children with more than grade one murmur on cardiac auscultation. We estimated the prevalence of RHD among school-attending children as the number of RHD cases per 1000 school-attending children with a 95% confidence interval. The database included a total of 107,340 children who were screened clinically, of whom 10,600 (9·9%) underwent transthoracic two-dimensional echocardiography. The overall prevalence of RHD was 2.22 cases per 1000 school-attending children (95% CI:1·94 - 2·50). The highest prevalence was observed among children living in the southern Terai ecological zone (2·89 per 1000, 95% CI (2·32-3·46)) of Nepal. Among the provinces, Karnali had the highest prevalence of RHD (3·45 per 1000, 95% CI (2·42-4·48)). Among the districts screened, Kalikot had the highest RHD prevalence (5.47 per 1000, 95% CI (3.02-7.92)). Primordial, primary and secondary prevention programmes should pay special attention to southern Terai zone, particularly the under-privileged children from remote districts.
1 November 2018 in Nepal Journal of Obstetrics and Gynaecology
Aims: To estimate the VIA positivity rate and to see the efficacy of the treatment with cryotherapy during follow up.Methods: A retrospective analysis of all VIA test from March 2012 to April 2015 were analyzed to estimate the VIA positivity rate of the screened population. Guideline for screening, treatment and follow up was as per the national guideline for cervical cancer screening and treatment 2010 of Nepal.Results: A total of 12,444 clients were screened, the VIA positivity rate was 5.9%, repeat VIA positivity rate at the end of one year during follow up was 1.2%, more than 98% had been screened for cervical cancer for the first time and the complication following cryotherapy was low.Conclusions: The VIA positivity rate of our population is comparable to the global magnitude. Screening for cervical cancer with VIA and treatment with cryotherapy is a feasible and acceptable form of screening in our setup. The recommendation would be scaling up of the facility up to grass root level that is linked to appropriate referral system.
19 May 2026 in Journal of the American Heart Association
Background: Hypertension management using home blood pressure monitoring–guided pharmacotherapy is more effective than clinic‐based care, but the benefit is attenuated in underserved patients. We evaluated implementation determinants of a team‐based telehealth hypertension management program providing home blood pressure monitoring–guided pharmacotherapy and self‐management and social support. Methods: We used Exploration, Preparation, Implementation and Sustainment, and Health Equity Implementation Frameworks for semistructured interviews and inductive/deductive coding using thematic analysis of qualitative data and quantitative analysis to evaluate team‐based telehealth hypertension management program implementation facilitators, barriers, acceptability, appropriateness, and feasibility. We purposefully sampled 20 patients with hypertension and 16 clinic key players from 2 safety‐net clinics in North Carolina. Quantitative measures were Acceptability of Intervention Measure, Intervention Appropriateness Measure, Feasibility of Intervention Measure, Patient Assessment of Chronic Illness Care, Organizational Readiness for Implementing Change (all measures' score ranged 1–5; higher score is better). We used concurrent embedded mixed methods (qualitative + quantitative) for convergence and complementarity. Results: Five qualitative themes emerged around (1) staffing barriers, coordinated teamwork, and friendly study tools; (2) the program's patient and provider centeredness; (3) ease of home blood pressure monitoring; (4) personalized, comprehensive self‐management calls; and (5) social support. Patients and clinic key players found the program acceptable (mean±SD, 4.42±0.84 and 4.56±0.59), appropriate (4.42±0.86 and 4.61±0.50), and feasible (4.40±0.89 and 4.44±0.53), respectively. Patient Assessment of Chronic Illness Care and Organizational Readiness for Implementing Change scores were 4.22±1.01 and 4.11±0.78, respectively. Conclusions: Implementing a team‐based telehealth hypertension management program depends on its tailoring to patients and providers and having their endorsement; a user‐friendly and trust‐promoting model; and having a viable financial plan. Future studies should assess clinical and cost effectiveness of the program. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05424744.
Introduction: Erdheim-Chester Disease (ECD) is a rare non-Langerhans cell histiocytosis with a propensity to involve multiple organs. Case presentation: We report a case of a patient in mid-60s with occipital headache and ataxia. Following the radiological and immunohistochemical investigations and genomic studies, a diagnosis of ECD was made with two intracerebral lesions. Brain lesions were resected and the patient was discharged with the medication Vemurafenib. After 3 years of diagnosis and 13 years of initial presentation, patient passed away. Discussion: ECD frequently presents with Diabetes Insipidus as initial presentation, long bone osteosclerosis as the most common presentation, and has multi-system predisposition. ECD can be differentiated from Langerhans Cell Histiocytosis (LCH) with immunohistochemistry images of the biopsy specimens. Further, with genomic analysis of ECD, the neoplastic nature has been highlighted and targeted therapies like Vemurafenib and Cobimetinib are shown to be effective. Conclusion: Good clinical judgement and supporting investigations can aid in diagnosing rare entities like ECD even in resource-limited settings. HIGHLIGHTS Rare case of Erdheim-Chester disease with multi-system involvement presenting with initial features 10 years prior to diagnosis. Initially Diabetes Insipidus, followed by long bone and other multi-system involvement important cues for the diagnosis. Biopsy of the lesion and immunohistochemical analysis can help confirm the diagnosis. Genomic studies with mutational analysis further highlights the neoplastic nature of the disease. Advancement of genomic studies with targeted therapies like Vemurafenib and Cobimetinib key in of management of ECD.